144 related articles for article (PubMed ID: 22070501)
1. In vitro effects of rituximab on the proliferation, activation and differentiation of human B cells.
Kamburova EG; Koenen HJ; Boon L; Hilbrands LB; Joosten I
Am J Transplant; 2012 Feb; 12(2):341-50. PubMed ID: 22070501
[TBL] [Abstract][Full Text] [Related]
2. A single dose of rituximab does not deplete B cells in secondary lymphoid organs but alters phenotype and function.
Kamburova EG; Koenen HJ; Borgman KJ; ten Berge IJ; Joosten I; Hilbrands LB
Am J Transplant; 2013 Jun; 13(6):1503-11. PubMed ID: 23570303
[TBL] [Abstract][Full Text] [Related]
3. Short- and long-term effects of anti-CD20 treatment on B cell ontogeny in bone marrow of patients with rheumatoid arthritis.
Rehnberg M; Amu S; Tarkowski A; Bokarewa MI; Brisslert M
Arthritis Res Ther; 2009; 11(4):R123. PubMed ID: 19686595
[TBL] [Abstract][Full Text] [Related]
4. Rituximab therapy reduces activated B cells in both the peripheral blood and bone marrow of patients with rheumatoid arthritis: depletion of memory B cells correlates with clinical response.
Nakou M; Katsikas G; Sidiropoulos P; Bertsias G; Papadimitraki E; Raptopoulou A; Koutala H; Papadaki HA; Kritikos H; Boumpas DT
Arthritis Res Ther; 2009; 11(4):R131. PubMed ID: 19715572
[TBL] [Abstract][Full Text] [Related]
5. Effects of rituximab therapy on B cell differentiation and depletion.
Bergantini L; d'Alessandro M; Cameli P; Vietri L; Vagaggini C; Perrone A; Sestini P; Frediani B; Bargagli E
Clin Rheumatol; 2020 May; 39(5):1415-1421. PubMed ID: 32088800
[TBL] [Abstract][Full Text] [Related]
6. Enhancement of Rituximab-induced cell death by the physical association of CD20 with CD40 molecules on the cell surface.
Al-Zoobi L; Salti S; Colavecchio A; Jundi M; Nadiri A; Hassan GS; El-Gabalawy H; Mourad W
Int Immunol; 2014 Aug; 26(8):451-65. PubMed ID: 24894009
[TBL] [Abstract][Full Text] [Related]
7. Treatment of inflammatory immunologic disease 4. B cell targeting therapy using the anti-CD20 antibody rituximab in inflammatory autoimmune diseases.
Tanaka Y
Intern Med; 2007; 46(16):1313-5. PubMed ID: 17704614
[No Abstract] [Full Text] [Related]
8. Differential Effects of Tacrolimus versus Sirolimus on the Proliferation, Activation and Differentiation of Human B Cells.
Traitanon O; Mathew JM; La Monica G; Xu L; Mas V; Gallon L
PLoS One; 2015; 10(6):e0129658. PubMed ID: 26087255
[TBL] [Abstract][Full Text] [Related]
9. Longitudinal analysis of T and B cell phenotype and function in renal transplant recipients with or without rituximab induction therapy.
Kamburova EG; Koenen HJ; van den Hoogen MW; Baas MC; Joosten I; Hilbrands LB
PLoS One; 2014; 9(11):e112658. PubMed ID: 25393622
[TBL] [Abstract][Full Text] [Related]
10. Effect of rituximab on B cell phenotype and serum B cell-activating factor levels in patients with thrombotic thrombocytopenic purpura.
Becerra E; Scully MA; Leandro MJ; Heelas EO; Westwood JP; De La Torre I; Cambridge G
Clin Exp Immunol; 2015 Mar; 179(3):414-25. PubMed ID: 25339550
[TBL] [Abstract][Full Text] [Related]
11. Internalization of rituximab and the efficiency of B Cell depletion in rheumatoid arthritis and systemic lupus erythematosus.
Reddy V; Cambridge G; Isenberg DA; Glennie MJ; Cragg MS; Leandro M
Arthritis Rheumatol; 2015 May; 67(8):2046-55. PubMed ID: 25916583
[TBL] [Abstract][Full Text] [Related]
12. Distinct in vitro binding properties of the anti-CD20 small modular immunopharmaceutical 2LM20-4 result in profound and sustained in vivo potency in cynomolgus monkeys.
Nickerson-Nutter C; Tchistiakova L; Seth NP; Kasaian M; Sibley B; Olland S; Zollner R; Brady WA; Mohler KM; Baum P; Wahl A; Herber D; Vugmeyster Y; Wensel D; Wolfman NM; Gill D; Collins M; Dunussi-Joannopoulos K
Rheumatology (Oxford); 2011 Jun; 50(6):1033-44. PubMed ID: 21258049
[TBL] [Abstract][Full Text] [Related]
13. Cytotoxic effects of the trifunctional bispecific antibody FBTA05 in ex-vivo cells of chronic lymphocytic leukaemia depend on immune-mediated mechanism.
Boehrer S; Schroeder P; Mueller T; Atz J; Chow KU
Anticancer Drugs; 2011 Jul; 22(6):519-30. PubMed ID: 21637160
[TBL] [Abstract][Full Text] [Related]
14. Induction of interleukin-6 production by rituximab in human B cells.
Jones JD; Hamilton BJ; Skopelja S; Rigby WF
Arthritis Rheumatol; 2014 Nov; 66(11):2938-46. PubMed ID: 25080282
[TBL] [Abstract][Full Text] [Related]
15. γδ T-cell killing of primary follicular lymphoma cells is dramatically potentiated by GA101, a type II glycoengineered anti-CD20 monoclonal antibody.
Braza MS; Klein B; Fiol G; Rossi JF
Haematologica; 2011 Mar; 96(3):400-7. PubMed ID: 21109686
[TBL] [Abstract][Full Text] [Related]
16. CD40-activated B cells from patients with systemic lupus erythematosus can be modulated by therapeutic immunoglobulins in vitro.
Néron S; Boire G; Dussault N; Racine C; de Brum-Fernandes AJ; Côté S; Jacques A
Arch Immunol Ther Exp (Warsz); 2009; 57(6):447-58. PubMed ID: 19866343
[TBL] [Abstract][Full Text] [Related]
17. Activation of human B cells by the agonist CD40 antibody CP-870,893 and augmentation with simultaneous toll-like receptor 9 stimulation.
Carpenter EL; Mick R; Rüter J; Vonderheide RH
J Transl Med; 2009 Nov; 7():93. PubMed ID: 19906293
[TBL] [Abstract][Full Text] [Related]
18. Effect of rituximab on human in vivo antibody immune responses.
Pescovitz MD; Torgerson TR; Ochs HD; Ocheltree E; McGee P; Krause-Steinrauf H; Lachin JM; Canniff J; Greenbaum C; Herold KC; Skyler JS; Weinberg A;
J Allergy Clin Immunol; 2011 Dec; 128(6):1295-1302.e5. PubMed ID: 21908031
[TBL] [Abstract][Full Text] [Related]
19. Effects of specific anti-B and/or anti-plasma cell immunotherapy on antibody production in baboons: depletion of CD20- and CD22-positive B cells does not result in significantly decreased production of anti-alphaGal antibody.
Alwayn IP; Xu Y; Basker M; Wu C; Buhler L; Lambrigts D; Treter S; Harper D; Kitamura H; Vitetta ES; Abraham S; Awwad M; White-Scharf ME; Sachs DH; Thall A; Cooper DK
Xenotransplantation; 2001 Aug; 8(3):157-71. PubMed ID: 11472623
[TBL] [Abstract][Full Text] [Related]
20. Depletion of peripheral blood B cells with Rituximab and phenotype characterization of the recovering population in a patient with follicular lymphoma.
Abulayha AM; Tabal SA; Shawesh EI; Elbasir MA; Elbanani AS; Lamami YM; Bredan A
Leuk Res; 2010 Mar; 34(3):307-11. PubMed ID: 19580998
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
